Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regulus Therapeutics Inc. (RGLS)  
$2.02 0.10 (5.21%) as of 4:30 Fri 5/24


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 145,981,000
Market Cap: 294.88(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.13 - $2.88
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 25,516 25,516 25,516
Total Sell Value $0 $30,379 $30,379 $30,379
Total People Sold 0 3 3 3
Total Sell Transactions 0 3 3 3
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 306
  Page 12 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Parshall B Lynne Director   –       •       •   2014-07-17 4 AS $6.58 $32,906 D/D (5,000) 7,021,050     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-17 4 AS $6.58 $32,906 D/D (5,000) 6,122,050     -
   Parshall B Lynne Director   –       •       •   2014-07-16 4 AS $6.59 $23,058 D/D (3,500) 7,026,050     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-16 4 AS $6.59 $23,058 D/D (3,500) 6,127,050     -
   Parshall B Lynne Director   –       •       •   2014-07-11 4 AS $6.48 $11,339 D/D (1,750) 7,029,550     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-11 4 AS $6.48 $11,339 D/D (1,750) 6,130,550     -
   Parshall B Lynne Director   –       •       •   2014-07-10 4 AS $6.69 $30,109 D/D (4,500) 7,031,300     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-10 4 AS $6.69 $30,109 D/D (4,500) 6,132,300     -
   Parshall B Lynne Director   –       •       •   2014-07-09 4 AS $7.08 $12,748 D/D (1,800) 7,035,800     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-09 4 AS $7.08 $12,748 D/D (1,800) 6,136,800     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-03 4 AS $8.07 $9,678 D/D (1,200) 6,138,600     -
   Parshall B Lynne Director   –       •       •   2014-07-03 4 AS $8.07 $9,678 D/D (1,200) 7,037,600     -
   Alnylam Pharmaceuticals, Inc. 10% Owner   –       –       •   2014-07-02 4 AS $8.07 $25,011 D/D (3,100) 6,139,800     -
   Parshall B Lynne Director   –       •       •   2014-07-02 4 AS $8.07 $25,011 D/D (3,100) 7,038,800     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-07-01 4 AS $8.11 $28,426 D/D (3,505) 0     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-07-01 4 OE $0.38 $1,332 D/D 3,505 3,505     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-07-01 4 AS $8.10 $20,260 D/D (2,500) 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-07-01 4 OE $1.74 $4,350 D/D 2,500 82,500     -
   Parshall B Lynne Director   –       •       •   2014-06-27 4 AS $7.91 $24,931 D/D (3,150) 7,041,900     -
   Parshall B Lynne Director   –       •       •   2014-06-26 4 AS $7.89 $13,408 D/D (1,700) 7,045,050     -
   Parshall B Lynne Director   –       •       •   2014-06-25 4 AS $7.84 $21,566 D/D (2,750) 7,046,750     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-06-17 4 AS $8.05 $40,227 D/D (5,000) 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-06-17 4 OE $1.74 $8,700 D/D 5,000 85,000     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-06-09 4 AS $7.14 $25,017 D/D (3,505) 0     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-06-09 4 OE $0.38 $1,332 D/D 3,505 3,505     -
  306 Records found
  Previous  10  11  12  13   
  Page 12 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us